An open-label, single-arm, 28-day safety trial of 137 infant patients aged 3 to <24 months in which efficacy was an exploratory objective
Decrease in mean treatable %BSA affected with atopic dermatitis from 28.1% at Baseline to 12.4% at Day 29.
EASI is an objective grading tool used to measure the severity and extent of AD
EASI=Eczema Area and Severity Index; SE=Standard error
Find out more about the proportion of patients who achieved Clear or Almost Clear at Day 29 as the primary endpoint
Learn more about 28-day, open-label, single-arm, safety study in 3 to <24-month-old patients14
*Eligible patients pay as little as $10
Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1
The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined.
PDE4=phosphodiesterase 4.
EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.